Isofluran-Piramal (Isoflurane)

Isoflurane works by enhancing the activity of the GABA_A receptor, which increases inhibitory neurotransmission in the brain, and by blocking NMDA receptors, reducing excitatory signals. This dual action depresses neuronal activity, leading to unconsciousness and analgesia required for anesthesia.

The specific dose and vaporizer concentration of Isofluran-Piramal are determined by the attending anesthesiologist based on the patient’s age, weight, medical condition, and the type of surgery. The prescriber sets the appropriate dosing regimen.

Isoflurane is classified as pregnancy category unknown, and its safety during pregnancy or lactation has not been established. Use in pregnant or breastfeeding patients should only occur when clearly justified by the clinical situation and after thorough risk assessment.

To order Isofluran-Piramal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Isoflurane offers a rapid onset and moderate potency compared with agents like sevoflurane or desflurane. It is less soluble in blood, allowing quicker emergence, but may cause more airway irritation. Choice of agent depends on patient factors, surgical requirements, and institutional preferences.

Isofluran-Piramal should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations to maintain stability and potency.

Isofluran-Piramal is supplied as a solution for inhalation and is administered via a calibrated vaporizer attached to a breathing circuit. The anesthesiologist adjusts the vaporizer concentration to achieve the desired anesthetic depth while monitoring the patient’s vital signs.

The most serious risks include malignant hyperthermia in susceptible individuals, severe hypotension or cardiovascular collapse, and rare hepatic or renal toxicity with prolonged exposure. Prompt recognition and management of these events are essential during anesthesia.

Isofluran-Piramal should be avoided in patients with a known susceptibility to malignant hyperthermia, severe cardiovascular instability, or significant airway obstruction that cannot be managed safely. Contraindications must be assessed by the anesthesiologist before use.